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Italian patients, homeopathy, herbal medicine and exercise by those
in the North. More money is spent on CAM in Northern Italy. No
differences emerged in terms of disease features, frequency and reasons
for using CAM, or perceived effects.
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Background and aim: Thiopurines are increasingly prescribed for dis-
ease activity control in inflammatory bowel disease (IBD). Thiopurine-
methyl-transferase (TPMT) genotype and phenotype is expected to be
majorly involved in bio-availability and toxicity of thiopurines, and it
may vary in different populations. Aim of this study was to explore
TPMT genotype and phenotype in a Northern Italian population of
healthy controls and IBD patients.
Material and methods: The study protocol was approved by local
Ethical Committee. All consecutive IBD out-patients (n=169) and 533
healthy controls (HC) were recruited. A blood sample was drawn, DNA
was extracted for genetic analyses and erytrocytes were separated.
Major TPMT genetic variants (TPMT*2, *3A, *3B, *3C) were anal-
ysed by means of standardised PCR techniques, while intra-erythrocyte
TMPT activity was analysed using a standardised high pressure liquid
chromatography (HPLC) assay.
Results: Genotype results: TPMT was mutated in 8/169 (4.7%; 95%CI
1.5-8%) IBD cases (7 heterozigous for *3A and 1 for *3C, respectively)
and in 34/533 (6.4%; 95%CI 4-8%) HC (28 heterozigous for *3A, 3
for *3B and 3 for *3C, respectively); the difference was not statistically
significant (p=0.549). Hardy Weinberg distribution was respected, no
mutant homozygous was observed among the cases or controls. No
significant differences were noted for any subgroup analysis.
TPMT activity results: the distribution of TPMT activity was different
in IBD cases, with distribution not-normal (p<0.001) and significantly
lower than among HC (however not-normally distributed, p=0.014).
TPMT activity figures are reported in Table 1.
Table 1. TPMT activity
TPMT p
nMol/h/g Hgb IQR
HC (n=533) 33.23 26.61-42.04 comparator
IBD cases (n=169) 27.16 21.45-46.85 0.0016
Crohn’s disease (n=79) 27.82 20.80-45.11 0.0175
Ulcerative/indeterminate colitis (n=90) 27.02 21.65-29.89 0.0168
No significant TPMT phenotype difference was noted based on IBD
subgroups based on TPMT genotype or on other clinical characteristic,
but we found that IBD patients on systemic steroids (n=16) had higher
median TPMT activity (46.54 nMol/h/g Hgb) compared to those not on
steroid treatment (n=153, 26.98 nMol/h/g Hgb), p=0.0023.
Conclusions: This is the first study of TPMT genotypic and phenotypic
evaluation on the same population in a Northern Italian population.
No difference was observed for TPMT genotype comparing cases and
controls. Allelic frequency was lower than expected. TPMT activity was
lower in IBD patients compared to healthy controls. Larger groups of
patients are under investigation in order to confirm these observations.
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Background and aim: The aim of our study is to assess short and
long-term efficacy of endoscopic dilation of symptomatic ileocolonic
strictures in patients with CD; the patients had previously underwent or
not intestinal resectional surgery.
Material and methods: Between January 2003 and November 2007
we treated 32 following patients (16 m and 16 f, age range 30-75 years;
22 had underwent intestinal resection; follow up 3-59 months, median
32 months). Strictures were located in ileum (4), in terminal ileum (6),
in ileocolonic anastomosis (19) and in the colon (3). All patients were
studied with colonoscopy and CT Enterography; in last 3 cases MR
enterography was performed. In endoscopically inaccessible strictures
or severe inflammation, patients were reassessed after 15 days of steroid
therapy. An endoscopic treatment was performed for strictures < than
8 cm whereas longer strictures were referred for surgical treatment.
Three days before and 7 days after dilation a steroid systemic therapy
was given. Endoscopic dilatation was performed with CRE balloon,
starting from a minimum calibre of 6 mm to a maximum of 20 mm;
within 8 hours from dilation the patients underwent blood test and X ray
of the abdomen. If the first attempt was deemed incomplete or partial,
a further dilation was performed in 2 weeks; if the second procedure
turned out to be inadequate, patient was referred to surgery (1 pts). CT
Enterography/MR enterography was performed after 7 days and in case
of good outcome, patients were included in a follow-up program with
clinical examination, colonoscopy and endoscopic pneumatic dilation
at 3 and 6 months. In our study a revaluation every 6 months or earlier
in case of symptoms was planned. Each patient underwent from 1 to 10
dilations (media 2,9; total dilations 110).
Results: Only 1 patient did not benefit from the treatment (therapeutic
efficacy 97%). In our follow up, 28 patients (87.5%) were asymp-
tomatic; 21(67%) presented mild strictures and have been treated again.
Three patients (9.5%) had recurrent strictures at 2 and 5 months and
despite further dilations, surgery was necessary (2 ileal, 1 anasto-
motic).
Conclusions: Endoscopic dilation should be considered as first-line
therapy for Crohn’s patients with short intestinal strictures. Further ran-
domized multicenter studies are still necessary to optimize endoscopic
and medical therapy and follow-up.
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Background and aim: The development of strictures has been reported
using anti-TNFa MoAbs in Crohn’s Disease (CD). The correlation
between anti-TNFa therapy and development of symptomatic stenosis
is unknown. Aim was to assess, in a prospective longitudinal study (and
in a retrospective analysis), the frequency of sub/obstructions in CD
pts treated with anti-TNFa therapies. Secondary aim was to evaluate
sonographic findings after anti-TNFa therapy.
Material and methods: Prospective longitudinal study. From jan 2004
to oct 2007, 20 CD pts (11 M, median age 41.5 yrs) were treated
with anti-TNFa MoAbs including Infliximab (n=11), Certolizumab
